GABA A Receptor Positive Modulators

Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator

Seizures

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-11"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">ZTALMY (ganaxolone) oral suspension contains ganaxolone, a neuroactive steroid gamma-aminobutyric acid A (GABA<span class="Sub">A</span>) receptor positive modulator. Ganaxolone (1-[(3R, 5S, 8R, 9S, 10S, 13S, 14S, 17S)-3-hydroxy-3, 10, 13-trimethyl-1, 2, 4, 5, 6, 7, 8, 9, 11, 12, 14, 15, 16, 17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone) is a methyl-substituted (at the 3β position) analog of the endogenous neurosteroid allopregnanolone, a derivative of progesterone. Its empirical formula is C<span class="Sub">22</span>H<span class="Sub">36</span>O<span class="Sub">2</span>, and the molecular weight is 332.53 g/mol. The chemical structure is:</p><div class="Figure"><img alt="Chemical Structure" src="ztalmy-01.jpg"/></div><p>Ganaxolone is a white to off-white crystalline powder that only exists in one crystal form and has low aqueous solubility.</p><p>ZTALMY is an oral suspension of ganaxolone. Each mL of oral suspension contains 50 mg of ganaxolone. Inactive ingredients include artificial cherry flavor, citric acid, hypromellose, methylparaben, polyvinyl alcohol, propylparaben, purified water, simethicone emulsion, sodium benzoate, sodium citrate, sodium lauryl sulfate, and sucralose.</p></section>

ZTALMY

ganaxolone

ganaxolone 50 MG/ML Oral Suspension

Ztalmy

ganaxolone 50 MG/ML Oral Suspension [Ztalmy]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Medication Guide 

Submit MSL Request 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Ztalmy Enrollment Form 

Enroll in Patient Savings Program 

Other HCP Resources 

About Ztalmy 

Patient Stories 

FAQs: Seizures associated with CDKL5 deficiency disorder (CDD)

Ztalmy One Support Program 

Patient Resources 

Instructions For Use: Seizures associated with CDKL5 Deficiency Disorder (CDD)

Ztalmy Start Guide 

Doctor Discussion Guide 

Caregiver Brochure 

Treatment Tracker 